Business Context and Reporting Period
Company: Abbott Laboratories (ABT)
Filing Type: Form 8-K (Current Report)
Date of Report: April 20, 2022
Reporting Period: First Quarter 2022
This filing announces the results of operations for the first quarter of 2022. The report incorporates a press release (Exhibit 99.1) by reference, which contains the detailed financial data.
Key Financial Metrics
The provided text serves as a cover sheet and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing references a press release for these details.
Non-GAAP Measures: The company utilizes non-GAAP financial measures, specifically "net earnings excluding specified items," to assess performance. Adjustments include:
- Acquisition-related expenses
- Restructuring actions and cost reduction initiatives
- Voluntary recall costs
- Regulatory costs and certain litigation
- Asset impairments
- Tax benefits/expense related to specified items and prior year resolutions
- Excess tax benefits from share-based compensation
- Intangible amortization expense
Material Changes
The filing text does not provide specific data regarding material changes in financial metrics compared to the prior comparable period. Investors must refer to the incorporated press release (Exhibit 99.1) for year-over-year comparisons.
Guidance, Outlook, and Risks
Management Commentary: Management states that non-GAAP measures provide greater visibility on ongoing business performance and are used internally to monitor results. However, the company cautions that these measures should be considered in addition to, not as a substitute for, GAAP financial measures.
Risks and Contingencies: The filing lists specific items excluded from non-GAAP calculations that represent potential risks or unusual events, including voluntary recalls, regulatory costs, litigation, and asset impairments.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific Q1 2022 revenue and earnings figures.
- Verify the reconciliation between GAAP and non-GAAP net earnings to understand the magnitude of excluded items.
- Assess the impact of specific excluded items such as the voluntary recall and restructuring costs on future quarters.
- Confirm if the company provided updated full-year guidance in the referenced press release.